The CALGB 9343 trial9 compared conventionally-fractionated whole breast RT and tamoxifen vs tamoxifen alone for women aged 70 years or older with T1N0, estrogen receptor–positive breast cancer, demonstrating that adjuvant RT can be reasonably omitted in this cohort. Here, ESR1 is linked to breast carcinoma.